Novartis confirms Alcon eye care unit spin off next monthNovartis has finalised plans for the long-awaited spin-off of its Alcon eye care business, announcing that the new Share XNovartis confirms Alcon eye care unit spin off next monthhttps://pharmaphorum.com/news/novartis-confirms-alcon-eye-care-unit-spin-off-next-month/
CEO of Novartis’ generics unit quits, sparking sale speculationRichard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of Share XCEO of Novartis’ generics unit quits, sparking sale speculationhttps://pharmaphorum.com/news/ceo-of-sandoz-unit-quits-sparking-speculation-over-sale/
Sandoz announces results of digital innovation ‘HACk’A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic Share XSandoz announces results of digital innovation ‘HACk’https://pharmaphorum.com/news/sandoz-announces-results-of-digital-innovation-hack/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Former Trump lawyer Cohen says Novartis ‘wanted him to be lobbyist’Novartis’ dodgy dealings with the Trump administration have come under fresh scrutiny, as his former personal lawyer Michael Share XFormer Trump lawyer Cohen says Novartis ‘wanted him to be lobbyist’https://pharmaphorum.com/news/novartis-wanted-former-trump-cohen-lobbyist/
Novartis licenses lipoprotein-lowering CVD drugExcited by strong phase II data, Novartis is exercising its option to license Akcea Therapeutics’ TQJ230, a treatment Share XNovartis licenses lipoprotein-lowering CVD drughttps://pharmaphorum.com/news/novartis-licenses-lipoprotein-lowering-cvd-drug/
Clinigen buys remaining rights to Novartis cancer drugUK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth Share XClinigen buys remaining rights to Novartis cancer drughttps://pharmaphorum.com/news/clinigen-buys-remaining-rights-to-novartis-cancer-drug/
Novartis and Lilly CEOs back Trump plans to cut drug pricesCEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health Share XNovartis and Lilly CEOs back Trump plans to cut drug priceshttps://pharmaphorum.com/news/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices/
NICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomaNICE has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for diffuse large B-cell lymphoma (DLBCL) in adults who did Share XNICE approves Novartis’ CAR-T therapy for diffuse large B-cell lymphomahttps://pharmaphorum.com/news/nice-approves-novartis-car-t-therapy-for-diffuse-large-b-cell-lymphoma/
